28 September 2012
The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mouse model of atherosclerosis
Jacek JawienABCDEFG, Justyna Toton-ZuranskaBCD, Katarzyna KusBCD, Malgorzata PawlowskaBCD, Rafal OlszaneckiAD, Ryszard KorbutADEDOI: 10.12659/MSM.883478
Med Sci Monit 2012; 18(10): BR389-393
Abstract
Background: The aim of this study was to investigate whether the 3 different substances that can decrease the development of atherosclerosis – nebivolol, AVE 0991 and doxycycline – could at the same time diminish the level of inflammatory indicators interleukin-6 (IL-6), interleukin-12 (IL-12), serum amyloid A (SAA), and monocyte chemotactic protein-1 (MCP-1). Material/Methods: Forty 8-week-old female apoE–knockout mice on the C57BL/6J background were divided into 4 groups and put on chow diet for 4 months. Three experimental groups received the same diet as a control group, mixed with AVE 0991 at a dose 0.58 µmol per kg of body weight per day, nebivolol at a dose 2.0 µmol per kg of body weight per day, and doxycycline at a dose 1.5 mg per kg of body weight per day. At the age of 6 months, the mice were sacrificed. Results: All inflammatory indicators (MCP-1, IL-6, IL-12 and SAA) were diminished by AVE 0991. There was also a tendency to lower MCP-1, IL-6, IL-12 and SAA levels by nebivolol and doxycycline; however, it did not reach statistical significance. Conclusions: Of the 3 presented substances, only AVE 0991 was able to diminish the rise of inflammatory markers. Therefore, drug manipulations in the renin-angiotensin-aldosterone axis seem to be the most promising in the future treatment of atherogenesis.
Keywords: Inflammation Mediators - blood, Imidazoles - therapeutic use, Ethanolamines - therapeutic use, Doxycycline - therapeutic use, Benzopyrans - therapeutic use, Atherosclerosis - drug therapy, Apolipoproteins E - metabolism, Mice, Inbred C57BL, Mice, Knockout
1041 1
Editorial
01 June 2023 : Editorial
Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic PreparednessDOI: 10.12659/MSM.941209
Med Sci Monit 2023; 29:e941209
In Press
08 Jun 2023 : Clinical Research
Risk Factors for New Vertebral Compression Fracture After Percutaneous Vertebral Augmentation: A Retrospect...Med Sci Monit In Press; DOI: 10.12659/MSM.940134
08 Jun 2023 : Clinical Research
A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted ...Med Sci Monit In Press; DOI: 10.12659/MSM.940124
08 Jun 2023 : Clinical Research
Burden of COVID-19 on Mental Health of Resident Doctors in PolandMed Sci Monit In Press; DOI: 10.12659/MSM.940208
08 Jun 2023 : Clinical Research
Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: Th...Med Sci Monit In Press; DOI: 10.12659/MSM.940251
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952